To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.
Specifications
- Antibody Type:Primary
- Antigen Name:DXd
- Clonality:Monoclonal
- Clone:39F4
- Conjugation:Unconjugated
- ELISA:Yes
- Host:Mouse
- Isotype:IgG2b kappa
- Reactivity:
- Size:40 μg
- Environmentally Preferable:
- Cross Adsorption:No
- Form:Liquid
- Storage Buffer:Supplied in PBS, pH 7.4, containing 0.02% ProClin300
- Storage Temperature:The product remains stable up to 1 year at −20 °C from date of receipt. Avoid repeated freezing and thawing cycles
- Concentration:0.5 mg/ml
- Immunogen:DXd-KLH
- Cat. No.:77007-650
- Packaging:Vial
Specifications
About this item
Payloads are the important components of antibody-drug conjugates (ADCs). The most commonly used ADC payloads are MMAE, DM1, and DXd. ADC pharmacokinetic (PK) studies include free payload analysis, conjugated antibody analysis, and total antibody analysis via ligand-binding assay (LBA) and LC-MS/MS assay. The anti-payload antibody is a useful reagent in PK assay for determining conjugated antibodies. It can be used as a capture antibody to determine the conjugated antibody in LBA assay or through immunocapture to enrich the ADC sample in LC-MS/MS assay. The DXd, also known as exatecan derivative, is a potent inhibitor of DNA topoisomerase I. Trastuzumab deruxtecan (T-DXd, DS-8201a or Enhertu®), composed of trastuzumab conjugated to DXd, is the first approved ADC for the treatment of breast cancer.
- High specificity
- High affinity
- High stability
GenScript offers highly specific monoclonal and polyclonal primary antibodies. These primary antibodies are validated for multiple applications, including Sandwich ELISA and western blot.
Type: Primary
Antigen: DXd
Clonality: Monoclonal
Clone: 39F4
Conjugation: Unconjugated
Epitope:
Host: Mouse
Isotype: IgG2b kappa
Reactivity: